menu
    • menu

    Find Bexarotene manufacturers, exporters & distributors on PharmaCompass

    Polfa Tarchomin is a leading Polish pharmaceutical company with 200 year tradition in manufacture and sale of pharmaceutical products.

    Virtual Booth

    Contact Supplier

    Aurigene is a global leader in accelerating drug innovation through discovery, development & manufacturing.

    Virtual Booth

    Contact Supplier

    Midas Pharma provides expertise in developing and supplying APIs, finished products, and intermediates.

    Virtual Booth

    Contact Supplier

    ChemWerth works in generic API development & supply, non-infringement patent strategy development and regulatory support.

    Virtual Booth

    Contact Supplier

    Mission CDMO team brings reliability, resourcefulness, & responsiveness in executing your development project.

    Virtual Booth

    Contact Supplier

    xyz-pharma-m-2025-01-06

    Virtual Booth

    Contact Supplier

    ACTIVE PHARMA INGREDIENTS

    INTERMEDIATES

    FINISHED DOSAGE FORMULATIONS

    DRUG PRODUCT COMPOSITIONS

    RELATED EXCIPIENT COMPANIES

    EXCIPIENTS BY APPLICATIONS

    DIGITAL CONTENT

    GLOBAL SALES INFORMATION

    MARKET PLACE

    PharmaCompass

    Synopsis

    Related ProductsRelated Products

    Synopsis

    ACTIVE PHARMA INGREDIENTS

    11

    API Suppliers

    API Suppliers

    7

    USDMF

    US DMFs Filed

    0

    CEP/COS

    CEP/COS Certifications

    0

    JDMF

    JDMFs Filed

    3

    EU WC

    EU WC

    0

    KDMF

    KDMF

    9

    NDC API

    NDC API

    0

    VMF

    NDC API

    7

    Listed Suppliers

    Other Suppliers

    API REF. PRICE (USD/KG)

    $
    $ 7,055

    MARKET PLACE

    3

    API

    1

    FDF

    1INTERMEDIATES

    FINISHED DOSAGE FORMULATIONS

    16

    FDF Dossiers

    FDF Dossiers

    11

    FDA Orange Book

    FDA (Orange Book)

    4

    Europe

    Europe

    0

    Canada

    Canada

    0

    Australia

    Australia

    0

    South Africa

    South Africa

    1

    Listed Dossiers

    Listed Dossiers

    0 DRUGS IN DEVELOPMENT

    FDF DossiersDRUG PRODUCT COMPOSITIONS

    REF. STANDARDS OR IMPURITIES

    0

    EDQM

    0

    USP

    0

    JP

    0

    Others

    PATENTS & EXCLUSIVITIES

    0

    US Patents

    0

    US Exclusivities

    0

    Health Canada Patents

    DIGITAL CONTENT

    0

    Data Compilation #PharmaFlow

    0

    Stock Recap #PipelineProspector

    0

    Weekly News Recap #Phispers

    11

    News #PharmaBuzz

    GLOBAL SALES INFORMATION

    US Medicaid

    NA

    Annual Reports

    NA

    Finished Drug Prices

    Listed Dossiers

    153 RELATED EXCIPIENT COMPANIES

    276EXCIPIENTS BY APPLICATIONS

    Chemistry

    Click the arrow to open the dropdown
    read-moreClick the button for full data set
    read-moreClick the button for full data set
    Also known as: 153559-49-0, Targretin, Targrexin, Lgd1069, Lgd 1069, Lgd-1069
    Molecular Formula
    C24H28O2
    Molecular Weight
    348.5  g/mol
    InChI Key
    NAVMQTYZDKMPEU-UHFFFAOYSA-N
    FDA UNII
    A61RXM4375
    Bexarotene
    A rexinoid (an RXR-binding ligand), tetrahydronaphthalene derivative and RETINOID X RECEPTOR antagonist that is used in the treatment of CUTANEOUS T-CELL LYMPHOMA.
    Bexarotene is a Retinoid.
    1 2D Structure

    Bexarotene

    2 Identification
    2.1 Computed Descriptors
    2.1.1 IUPAC Name
    4-[1-(3,5,5,8,8-pentamethyl-6,7-dihydronaphthalen-2-yl)ethenyl]benzoic acid
    2.1.2 InChI
    InChI=1S/C24H28O2/c1-15-13-20-21(24(5,6)12-11-23(20,3)4)14-19(15)16(2)17-7-9-18(10-8-17)22(25)26/h7-10,13-14H,2,11-12H2,1,3-6H3,(H,25,26)
    2.1.3 InChI Key
    NAVMQTYZDKMPEU-UHFFFAOYSA-N
    2.1.4 Canonical SMILES
    CC1=CC2=C(C=C1C(=C)C3=CC=C(C=C3)C(=O)O)C(CCC2(C)C)(C)C
    2.2 Other Identifiers
    2.2.1 UNII
    A61RXM4375
    2.3 Synonyms
    2.3.1 MeSH Synonyms

    1. 3-methyl-ttneb

    2. 4-(1-(3,5,5,8,8-pentamethyl-5,6,7,8-tetrahydro-2-naphthyl)ethenyl)benzoic Acid

    3. Lg69 Compound

    4. Lgd 1069

    5. Lgd-1069

    6. Lgd1069

    7. Targretin

    2.3.2 Depositor-Supplied Synonyms

    1. 153559-49-0

    2. Targretin

    3. Targrexin

    4. Lgd1069

    5. Lgd 1069

    6. Lgd-1069

    7. Lg100069

    8. 166175-31-1

    9. 4-[1-(3,5,5,8,8-pentamethyl-6,7-dihydronaphthalen-2-yl)ethenyl]benzoic Acid

    10. 4-(1-(3,5,5,8,8-pentamethyl-5,6,7,8-tetrahydronaphthalen-2-yl)vinyl)benzoic Acid

    11. P-(1-(5,6,7,8-tetrahydro-3,5,5,8,8-pentamethyl-2-naphthyl)vinyl)benzoic Acid

    12. Targretyn

    13. Lg 100069

    14. Lg-100069

    15. 4-[1-(3,5,5,8,8-pentamethyl-5,6,7,8-tetrahydro-naphthalen-2-yl)-vinyl]-benzoic Acid

    16. 4-[1-(3,5,5,8,8-pentamethyl-5,6,7,8-tetrahydronaphthalen-2-yl)ethenyl]benzoic Acid

    17. Nsc-747528

    18. Chembl1023

    19. 4-(1-(5,6,7,8-tetrahydro-3,5,5,8,8-pentamethyl-2-naphthalenyl)ethenyl)benzoic Acid

    20. Targret

    21. Chebi:50859

    22. A61rxm4375

    23. 4-[1-(5,6,7,8-tetrahydro-3,5,5,8,8-pentamethyl-2-naphthalenyl)ethenyl]benzoic Acid

    24. Bexarotene [usan]

    25. Ncgc00181016-01

    26. Ro 26-4455

    27. Sr 11247

    28. 4-[1-(3,5,5,8,8-pentamethyl-5,6,7,8-tetrahydronaphthalen-2-yl)vinyl]benzoic Acid

    29. Dsstox_cid_20619

    30. Dsstox_rid_79514

    31. Dsstox_gsid_40619

    32. Bexaroteno

    33. Bexarotenum

    34. Bexaroten

    35. Lg 1069

    36. 4-[1-(3,5,5,8,8-pentamethyl-5,6,7,8-tetrahydro-naphthalen-2-yl)-vinyl]benzoic Acid

    37. Targretin (tn)

    38. Cas-153559-49-0

    39. Hsdb 7453

    40. Sr-05000001480

    41. Bexarotene [usan:inn:ban]

    42. Unii-a61rxm4375

    43. Dtxsid1040619

    44. 4-[1-(5,6,7,8-tetrahydro-3,5,5,8,8-pentamethyl-2-naphthalenyl)ethenyl)benzoic Acid

    45. Lg 69

    46. Bexarotene- Bio-x

    47. 4-(1-(3,5,5,8,8-pentamethyl-5,6,7,8-tetrahydro-naphthalen-2-yl)vinyl)benzoic Acid

    48. Mfcd00932428

    49. Bexarotene-[13c4]

    50. 4k6i

    51. Bexarotene [mi]

    52. Bexarotene [inn]

    53. Bexarotene [jan]

    54. Bexarotene [hsdb]

    55. Bexarotene Oral(targretin)

    56. Bexarotene [vandf]

    57. Bexarotene [mart.]

    58. Schembl9025

    59. Bexarotene [who-dd]

    60. Bidd:pxr0021

    61. Mls006010146

    62. Bexarotene (jan/usan/inn)

    63. Bexarotene [ema Epar]

    64. Gtpl2807

    65. Bexarotene [orange Book]

    66. Bexarotene, >=98% (hplc)

    67. Hms2089l14

    68. Hms3655d19

    69. Hms3747c21

    70. Hms3884b07

    71. 4-[1-(1,1,4,4,7-pentamethyltetralin-6-yl)vinyl]benzoic Acid

    72. Act03911

    73. Amy24869

    74. Bcp04099

    75. Zinc1539579

    76. Tox21_112666

    77. Tox21_302407

    78. Bdbm50032675

    79. Dl-298

    80. Nsc747528

    81. Nsc783322

    82. S2098

    83. Akos015902814

    84. Tox21_112666_1

    85. Bcp9000396

    86. Ccg-221823

    87. Cs-0626

    88. Db00307

    89. Nsc 741061

    90. Nsc 747528

    91. Nsc-783322

    92. Sb17341

    93. Ss-4628

    94. Benzoic Acid, 4-(1-(5,6,7,8-tetrahydro-3,5,5,8,8-pentamethyl-2-naphthalenyl)ethenyl)-

    95. Ncgc00181016-02

    96. Ncgc00181016-03

    97. Ncgc00181016-04

    98. Ncgc00181016-08

    99. Ncgc00181016-20

    100. Ncgc00255426-01

    101. Ac-24569

    102. Bb164246

    103. Hy-14171

    104. Smr001614557

    105. Bcp0726000106

    106. Ft-0657110

    107. Ft-0702645

    108. Sw203810-3

    109. D03106

    110. Ab01275475-01

    111. Ab01275475_02

    112. 559b490

    113. A809441

    114. Q418192

    115. J-009026

    116. J-519847

    117. Sr-05000001480-1

    118. Sr-05000001480-2

    119. Brd-k92441787-001-02-5

    120. 4,6-dichloro-2,3-dihydro-1h-indolehydrochloride

    121. 4-[1-(3,5,5,8,8-pentamethyltetralin-2-yl)ethenyl]benzoic Acid

    122. 4-[1-(3,5,5,8,8-pentamethyl-2-5,8-dihydronaphthyl)vinyl]benzoic Acid

    123. 4-[1-(3,5,5,8,8-pentamethyl-5,6,7,8-tetrahydro-2-naphthyl)ethenyl]benzoic Acid

    124. 4-[1-(3,5,5,8,8-pentamethyl-5,6,7,8-tetrahydronaphthalen-2-yl)-vinyl]benzoic Acid

    125. 4-[1-(5,6,7,8,-tetrahydro-3,5,5,8,8-pentamethyl-2-naphtalenyl)ethenyl]benzoic Acid

    126. 4-[1-(5,6,7,8-tetrahydro-3,5,5,8,8-pentamethyl-2-naphthalenyl)-1-ethenyl]benzoic Acid

    127. Benzoic Acid,6,7,8-tetrahydro-3,5,5,8,8-pentamethyl-2-naphthalenyl)ethenyl]-

    2.4 Create Date
    2005-08-08
    3 Chemical and Physical Properties
    Molecular Weight 348.5 g/mol
    Molecular Formula C24H28O2
    XLogP37.6
    Hydrogen Bond Donor Count1
    Hydrogen Bond Acceptor Count2
    Rotatable Bond Count3
    Exact Mass348.208930132 g/mol
    Monoisotopic Mass348.208930132 g/mol
    Topological Polar Surface Area37.3 Ų
    Heavy Atom Count26
    Formal Charge0
    Complexity551
    Isotope Atom Count0
    Defined Atom Stereocenter Count0
    Undefined Atom Stereocenter Count0
    Defined Bond Stereocenter Count0
    Undefined Bond Stereocenter Count0
    Covalently Bonded Unit Count1
    4 Drug and Medication Information
    4.1 Drug Information
    1 of 2  
    Drug NameTargretin
    PubMed HealthBexarotene
    Drug ClassesAntineoplastic Agent, Antineoplastic, Dermatological, Dermatological Agent
    Drug LabelTargretin (bexarotene) is a member of a subclass of retinoids that selectively activate retinoid X receptors (RXRs). These retinoid receptors have biologic activity distinct from that of retinoic acid receptors (RARs). Each soft gelatin capsule for o...
    Active IngredientBexarotene
    Dosage FormCapsule; Gel
    RouteOral; Topical
    Strength1%; 75mg
    Market StatusPrescription
    CompanyValeant Luxembourg

    2 of 2  
    Drug NameTargretin
    PubMed HealthBexarotene
    Drug ClassesAntineoplastic Agent, Antineoplastic, Dermatological, Dermatological Agent
    Drug LabelTargretin (bexarotene) is a member of a subclass of retinoids that selectively activate retinoid X receptors (RXRs). These retinoid receptors have biologic activity distinct from that of retinoic acid receptors (RARs). Each soft gelatin capsule for o...
    Active IngredientBexarotene
    Dosage FormCapsule; Gel
    RouteOral; Topical
    Strength1%; 75mg
    Market StatusPrescription
    CompanyValeant Luxembourg

    4.2 Therapeutic Uses

    THERAP CAT: Antineoplastic

    O'Neil, M.J. (ed.). The Merck Index - An Encyclopedia of Chemicals, Drugs, and Biologicals. 13th Edition, Whitehouse Station, NJ: Merck and Co., Inc., 2001., p. 203

    Bexarotene is indicated for the treatment of cutaneous manifestations of cutaneous T-cell lyphoma in patients who are refractory to at least one other prior systemic therapy. /Included in US product label/

    Thomson/Micromedex. Drug Information for the Health Care Professional. Volume 1, Greenwood Village, CO. 2006., p. 615

    4.3 Drug Warning

    May cause fetal harm; teratogenicity and embryolethality demonstrated in animals. No adequate and well-controlled studies to date in humans. Pregnancy should be avoided during therapy. If used during pregnancy, apprise of potential fetal hazard. ... Male patients receiving the drug should use condoms during sexual intercourse with women who are or may become pregnant.

    McEvoy, G.K. (ed.). American Hospital Formulary Service. AHFS Drug Information. American Society of Health-System Pharmacists, Bethesda, MD. 2006., p. 939

    Effective contraception must be used for one month prior to the initiation of therapy, during therapy and for at least one month following discontinuation of therapy; it is recommended that two reliable forms of contraception be used simultaneously unless abstinence is the chosen method. Bexarotene can potentially induce metabolic enzymes and thereby theoretically reduce the plasma concentrations of oral or other systemic hormonal contraceptives.

    Physicians Desk Reference 60th ed, Thomson PDR, Montvale, NJ 2006., p. 1720

    Hyperlipidemia occurred in 79% of patients receiving oral bexarotene in phase II-III clinical studies. Elevations in fasting triglycerides and cholesterol and decreases in HDL-cholesterol were observed in more than half of patients receiving 300 mg/sq m or more. Lipid abnormalities usually developed within 2-4 weeks and were reversible with cessation of therapy. If fasting triglycerides are elevated or become elevated during treatment, antilipemic therapy should be instituted, and the dosage of bexarotene reduced or suspended.

    McEvoy, G.K. (ed.). American Hospital Formulary Service. AHFS Drug Information. American Society of Health-System Pharmacists, Bethesda, MD. 2006., p. 939

    Acute pancreatitis has been reported in several patients treated with bexarotene and has been fatal in at least one patient. The manufacturer states that patients with cutaneous T-cell lymphoma (CTCL) who have risk factors for pancreatitis (eg, prior pancreatitis, uncontrolled hyperlipidemia, excessive alcohol consumption, uncontrolled diabetes mellitus, biliary tract disease, or drugs associated with pancreatic toxicity or known to increase triglyceride concentrations) generally should not be treated with bexarotene.

    McEvoy, G.K. (ed.). American Hospital Formulary Service. AHFS Drug Information. American Society of Health-System Pharmacists, Bethesda, MD. 2006., p. 939

    For more Drug Warnings (Complete) data for BEXAROTENE (15 total), please visit the HSDB record page.

    4.4 Drug Indication

    Used orally for the treatment of skin manifestations of cutaneous T-cell lymphoma (CTCL) in patients who are refractory to at least one prior systemic therapy. Also used topically for the treatment of skin lesions in early (stage IA and IB) CTCL in patients who experience refractory or persistent disease with the use of other therapies or are intolerant of other therapies.

    FDA Label

    Targretin capsules are indicated for the treatment of skin manifestations of advanced stage cutaneous T-cell lymphoma (CTCL) patients refractory to at least one systemic treatment.

    5 Pharmacology and Biochemistry
    5.1 Pharmacology

    Bexarotene is a member of a subclass of retinoids that selectively activate retinoid X receptors (RXRs). These retinoid receptors have biologic activity distinct from that of retinoic acid receptors (RARs). Bexarotene is indicated for the treatment of cutaneous manifestations of cutaneous T-cell lymphoma in patients who are refractory to at least one prior systemic therapy. Bexarotene selectively binds and activates retinoid X receptor subtypes (RXR, RXR, RXR). RXRs can form heterodimers with various receptor partners such as retinoic acid receptors (RARs), vitamin D receptor, thyroid receptor, and peroxisome proliferator activator receptors (PPARs). Once activated, these receptors function as transcription factors that regulate the expression of genes that control cellular differentiation and proliferation. Bexarotene inhibits the growth in vitro of some tumor cell lines of hematopoietic and squamous cell origin. It also induces tumor regression in vivo in some animal models.

    5.2 MeSH Pharmacological Classification

    Antineoplastic Agents

    Substances that inhibit or prevent the proliferation of NEOPLASMS. (See all compounds classified as Antineoplastic Agents.)

    5.3 FDA Pharmacological Classification
    5.3.1 Active Moiety
    BEXAROTENE
    5.3.2 FDA UNII
    A61RXM4375
    5.3.3 Pharmacological Classes
    Retinoids [CS]; Retinoid [EPC]
    5.4 ATC Code

    L01XF03

    L01XX25

    S76 | LUXPHARMA | Pharmaceuticals Marketed in Luxembourg | Pharmaceuticals marketed in Luxembourg, as published by d'Gesondheetskeess (CNS, la caisse nationale de sante, www.cns.lu), mapped by name to structures using CompTox by R. Singh et al. (in prep.). List downloaded from https://cns.public.lu/en/legislations/textes-coordonnes/liste-med-comm.html. Dataset DOI:10.5281/zenodo.4587355

    L - Antineoplastic and immunomodulating agents

    L01 - Antineoplastic agents

    L01X - Other antineoplastic agents

    L01XF - Retinoids for cancer treatment

    L01XF03 - Bexarotene

    5.5 Absorption, Distribution and Excretion

    Route of Elimination

    Urinary elimination of bexarotene and its known metabolites is a minor excretory pathway (<1% of administered dose).

    After oral administration, bexarotene is absorbed with a Tmax of about two hours. ...Studies in patients with advanced malignancies show approximate single dose linearity within the therapeutic range and low accumulation with multiple doses. Plasma bexarotene AUC and Cmax values resulting from a 75 to 300 mg dose were 35% and 48% higher, respectively, after a fat-containing meal than after a glucose solution. Bexarotene is highly bound (>99%) to plasma proteins. The plasma proteins to which bexarotene binds have not been elucidated, and the ability of bexarotene to displace drugs bound to plasma proteins and the ability of drugs to displace bexarotene binding have not been studied.

    Physicians Desk Reference 60th ed, Thomson PDR, Montvale, NJ 2006., p. 1719

    The renal elimination of bexarotene and its metabolites was examined in patients with Type 2 diabetes mellitus. Neither bexarotene nor its metabolites were excreted in urine in appreciable amounts. Bexarotene is thought to be eliminated primarily through the hepatobiliary system.

    Physicians Desk Reference 60th ed, Thomson PDR, Montvale, NJ 2006., p. 1719

    5.6 Metabolism/Metabolites

    Four bexarotene metabolites have been identified in plasma: 6- and 7-hydroxy-bexarotene and 6- and 7-oxo-bexarotene. In vitro studies suggest that cytochrome P450 3A4 is the major cytochrome P450 responsible for formation of the oxidative metabolites and that the oxidative metabolites may be glucuronidated. The oxidative metabolites are active in in vitro assays of retinoid receptor activation, but the relative contribution of the parent and any metabolites to the efficacy and safety of /bexarotene/ is unknown.

    Physicians Desk Reference 60th ed, Thomson PDR, Montvale, NJ 2006., p. 1719

    Bexarotene has known human metabolites that include 6-hydroxy-bexarotene, 7-hydroxy-bexarotene, and 7-oxo-bexarotene.

    S73 | METXBIODB | Metabolite Reaction Database from BioTransformer | DOI:10.5281/zenodo.4056560

    5.7 Biological Half-Life

    7 hours

    Terminal half-life of bexarotene is about seven hours.

    Physicians Desk Reference 60th ed, Thomson PDR, Montvale, NJ 2006., p. 1719

    5.8 Mechanism of Action

    Bexarotene selectively binds with and activates retinoid X receptor subtypes. There are three subtypes in total: RXR, RXR, RXR. The exact mechanism of action of bexarotene in the treatment of CTCL is unknown but the drug has activity in all clinical stages of CTCL.

    Bexarotene selectively binds and activates retinoid X receptor subtypes (RXR(alpha), RXR(beta), RXR(gamma)). RXRs can form heterodimers with various receptor partners such as retinoic acid receptors (RARs), vitamin D receptor, thyroid receptor, and peroxisome proliferator activator receptors (PPARs). Once activated, these receptors function as transcription factors that regulate the expression of genes that control cellular differentiation and proliferation. Bexarotene inhibits the growth in vitro of some tumor cell lines of hematopoietic and squamous cell origin. It also induces tumor regression in vivo in some animal models. The exact mechanism of action of bexarotene in the treatment of cutaneous T-cell lymphoma (CTCL) is unknown.

    Physicians Desk Reference 60th ed, Thomson PDR, Montvale, NJ 2006., p. 1719

    API Reference Price

    read-more
    read-more
    [{"dataSource":"API Export","activeIngredients":"BEXAROTENE","year":"2021","qtr":"Q1","strtotime":1615141800,"product":"BEXAROTENE (TAX INVOICE NO:1905205303 DT 04.03.2021)(GROUP:A","address":"8-3-167\/D\/16, KALYAN NAGAR - I,VENGAL RAO NAGAR","city":"HYDERABAD, A.P.","supplier":"MSN LABORATORIES","supplierCountry":"INDIA","foreign_port":"CHICAGO O\\'HARE INT\\'L","customer":"LGM PHARMA","customerCountry":"UNITED STATES","quantity":"1.00","actualQuantity":"1","unit":"KGS","unitRateFc":"17863.4","totalValueFC":"17679.1","currency":"USD","unitRateINR":1287061,"date":"08-Mar-2021","totalValueINR":"1287061","totalValueInUsd":"17679.1","indian_port":"HYDERABAD AIR","hs_no":"29162090","bill_no":"9186961","productDescription":"API","marketType":"REGULATED MARKET","country":"UNITED STATES","selfForZScoreResived":"Pharma Grade","supplierPort":"HYDERABAD AIR","supplierAddress":"8-3-167\/D\/16, KALYAN NAGAR - I,VENGAL RAO NAGAR, HYDERABAD, A.P.","customerAddress":""},{"dataSource":"API Export","activeIngredients":"","year":"2021","qtr":"Q2","strtotime":1622485800,"product":"BEXAROTENE IH BATCH NOS:BX18010002","address":"HETERO HOUSE,H.NO.8-3-166\/7\/1ERRAGADDA","city":"HYDERABAD","supplier":"HETERO DRUGS","supplierCountry":"INDIA","foreign_port":"BUENOS AIRES BA","customer":"M\/S.CATALENT ARGENTINA S.A.I.C.","customerCountry":"ARGENTINA","quantity":"2.77","actualQuantity":"2.77","unit":"KGS","unitRateFc":"7439.1","totalValueFC":"20187.3","currency":"USD","unitRateINR":535989.62093862821,"date":"01-Jun-2021","totalValueINR":"1484691.25","totalValueInUsd":"20187.3","indian_port":"HYDERABAD AIR","hs_no":"29163110","bill_no":"2136451","productDescription":"API","marketType":"LESS REGULATED MARKET","country":"ARGENTINA","selfForZScoreResived":"Pharma Grade","supplierPort":"HYDERABAD AIR","supplierAddress":"HETERO HOUSE,H.NO.8-3-166\/7\/1ERRAGADDA, HYDERABAD","customerAddress":""},{"dataSource":"API Export","activeIngredients":"","year":"2021","qtr":"Q4","strtotime":1636137000,"product":"BEXAROTENE (TAX INVOICE NO:1905215254 DT","address":"8-3-167\/D\/16, KALYAN NAGAR - I,VENGAL RAO NAGAR","city":"HYDERABAD, A.P.","supplier":"MSN LABORATORIES","supplierCountry":"INDIA","foreign_port":"HAMBURG - FUHLSBUETT","customer":"F&A PHARMA HANDELS ","customerCountry":"GERMANY","quantity":"0.05","actualQuantity":"0.05","unit":"KGS","unitRateFc":"25000","totalValueFC":"1128","currency":"USD","unitRateINR":1680000,"date":"06-Nov-2021","totalValueINR":"84000","totalValueInUsd":"1128","indian_port":"HYDERABAD AIR","hs_no":"29162090","bill_no":"5831872","productDescription":"API","marketType":"REGULATED MARKET","country":"GERMANY","selfForZScoreResived":"Pharma Grade","supplierPort":"HYDERABAD AIR","supplierAddress":"8-3-167\/D\/16, KALYAN NAGAR - I,VENGAL RAO NAGAR, HYDERABAD, A.P.","customerAddress":""},{"dataSource":"API Export","activeIngredients":"","year":"2022","qtr":"Q2","strtotime":1650479400,"product":"BEXAROTENE IH","address":"HETERO CORPORATE, NO. 7-2-A2, INDUSTRIAL ESTATE,SANATHNAGAR Conta","city":"HYDERABAD","supplier":"HETERO DRUGS","supplierCountry":"INDIA","foreign_port":"ISTANBUL","customer":"ULKAR HOLDING","customerCountry":"TURKEY","quantity":"3.00","actualQuantity":"3","unit":"KGS","unitRateFc":"12000","totalValueFC":"35759.3","currency":"USD","unitRateINR":899333.33333333337,"date":"21-Apr-2022","totalValueINR":"2698000","totalValueInUsd":"35759.3","indian_port":"HYDERABAD AIR","hs_no":"29163110","bill_no":"9851461","productDescription":"API","marketType":"LESS REGULATED MARKET","country":"TURKEY","selfForZScoreResived":"Pharma Grade","supplierPort":"HYDERABAD AIR","supplierAddress":"HETERO CORPORATE, NO. 7-2-A2, INDUSTRIAL ESTATE,SANATHNAGAR Conta, HYDERABAD","customerAddress":""},{"dataSource":"API Export","activeIngredients":"","year":"2022","qtr":"Q2","strtotime":1652121000,"product":"BEXAROTENE (TAX INVOICE NO:1905225039 DT","address":"MSN HOUSE, PLOT NO. C-24,INDUSTRIAL HYDERABAD","city":"HYDERABAD","supplier":"MSN LABORATORIES","supplierCountry":"INDIA","foreign_port":"TORONTO","customer":"CONTRACT PHARMACEUTICALS","customerCountry":"CANADA","quantity":"0.10","actualQuantity":"0.1","unit":"KGS","unitRateFc":"12000","totalValueFC":"1048.1","currency":"USD","unitRateINR":810000,"date":"10-May-2022","totalValueINR":"81000","totalValueInUsd":"1048.1","indian_port":"HYDERABAD AIR","hs_no":"29162090","bill_no":"1284006","productDescription":"API","marketType":"REGULATED MARKET","country":"CANADA","selfForZScoreResived":"Pharma Grade","supplierPort":"HYDERABAD AIR","supplierAddress":"MSN HOUSE, PLOT NO. C-24,INDUSTRIAL HYDERABAD, HYDERABAD","customerAddress":""},{"dataSource":"API Export","activeIngredients":"","year":"2022","qtr":"Q4","strtotime":1672252200,"product":"BEXAROTENE IH","address":"HETERO CORPORATE, NO. 7-2-A2, INDUSTRIAL ESTATE,SANATHNAGAR CONTA","city":"HYDERABAD","supplier":"HETERO DRUGS","supplierCountry":"INDIA","foreign_port":"ISTANBUL","customer":"TO THE ORDER OF.., ..,.. ,,..,","customerCountry":"TURKEY","quantity":"2.50","actualQuantity":"2.5","unit":"KGS","unitRateFc":"8000","totalValueFC":"19767.9","currency":"USD","unitRateINR":651600,"date":"29-Dec-2022","totalValueINR":"1629000","totalValueInUsd":"19767.9","indian_port":"HYDERABAD AIR","hs_no":"29163110","bill_no":"6537450","productDescription":"API","marketType":"LESS REGULATED MARKET","country":"TURKEY","selfForZScoreResived":"Pharma Grade","supplierPort":"HYDERABAD AIR","supplierAddress":"HETERO CORPORATE, NO. 7-2-A2, INDUSTRIAL ESTATE,SANATHNAGAR CONTA, HYDERABAD","customerAddress":""},{"dataSource":"API Export","activeIngredients":"","year":"2023","qtr":"Q3","strtotime":1689359400,"product":"BEXAROTENE IH","address":"HETERO CORPORATE, NO. 7-2-A2, INDUSTRIAL ESTATE,SANATHNAGAR Conta","city":"HYDERABAD","supplier":"HETERO DRUGS","supplierCountry":"INDIA","foreign_port":"BUENOS AIRES, BA","customer":"TO THE ORDER OF , . , . ,. ,,,,","customerCountry":"ARGENTINA","quantity":"6.00","actualQuantity":"6","unit":"KGS","unitRateFc":"7000","totalValueFC":"41501.6","currency":"USD","unitRateINR":568499.97750000004,"date":"15-Jul-2023","totalValueINR":"3410999.865","totalValueInUsd":"41501.6","indian_port":"HYDERABAD AIR","hs_no":"29163110","bill_no":"0","productDescription":"API","marketType":"LESS REGULATED MARKET","country":"ARGENTINA","selfForZScoreResived":"Pharma Grade","supplierPort":"HYDERABAD AIR","supplierAddress":"HETERO CORPORATE, NO. 7-2-A2, INDUSTRIAL ESTATE,SANATHNAGAR Conta, HYDERABAD","customerAddress":""},{"dataSource":"API Export","activeIngredients":"","year":"2023","qtr":"Q4","strtotime":1696530600,"product":"BEXAROTENE IH","address":"HETERO CORPORATE, NO. 7-2-A2,","city":"HYDERABAD","supplier":"HETERO DRUGS","supplierCountry":"INDIA","foreign_port":"ISTANBUL","customer":"TO THE ORDER OF","customerCountry":"TURKEY","quantity":"0.21","actualQuantity":"0.214","unit":"KGS","unitRateFc":"12000","totalValueFC":"2487.1","currency":"USD","unitRateINR":967289.71962616825,"date":"06-Oct-2023","totalValueINR":"207000","totalValueInUsd":"2487.1","indian_port":"Hyderabad Air","hs_no":"29163110","bill_no":"4436886","productDescription":"API","marketType":"LESS REGULATED MARKET","country":"TURKEY","selfForZScoreResived":"Pharma Grade","supplierPort":"Hyderabad Air","supplierAddress":"HETERO CORPORATE, NO. 7-2-A2,, HYDERABAD","customerAddress":""},{"dataSource":"API Export","activeIngredients":"","year":"2023","qtr":"Q4","strtotime":1703097000,"product":"BEXAROTENE","address":"MSN HOUSE, PLOT NO. C-24,","city":"HYDERABAD. AP","supplier":"MSN LABORATORIES","supplierCountry":"INDIA","foreign_port":"WUHAN","customer":"WUHAN HUMANWELL HI-TECH INDUSTRY CO. LTD","customerCountry":"CHINA","quantity":"0.50","actualQuantity":"0.5","unit":"KGS","unitRateFc":"18000","totalValueFC":"8865.6","currency":"USD","unitRateINR":1476000,"date":"21-Dec-2023","totalValueINR":"738000","totalValueInUsd":"8865.6","indian_port":"Hyderabad Air","hs_no":"29162090","bill_no":"6195065","productDescription":"API","marketType":"REGULATED MARKET","country":"CHINA","selfForZScoreResived":"Pharma Grade","supplierPort":"Hyderabad Air","supplierAddress":"MSN HOUSE, PLOT NO. C-24,, HYDERABAD. AP","customerAddress":""},{"dataSource":"API Export","activeIngredients":"","year":"2024","qtr":"Q1","strtotime":1704738600,"product":"BEXAROTENE IH","address":"HETERO CORPORATE, NO. 7-2-A2,","city":"HYDERABAD","supplier":"HETERO DRUGS","supplierCountry":"INDIA","foreign_port":"ISTANBUL","customer":"ULKAR HOLDING","customerCountry":"TURKEY","quantity":"0.10","actualQuantity":"0.098","unit":"KGS","unitRateFc":"12000","totalValueFC":"1092.8","currency":"USD","unitRateINR":926781.53061224485,"date":"09-Jan-2024","totalValueINR":"90824.59","totalValueInUsd":"1092.8","indian_port":"Hyderabad Air","hs_no":"29163190","bill_no":"6614055","productDescription":"API","marketType":"LESS REGULATED MARKET","country":"TURKEY","selfForZScoreResived":"Pharma Grade","supplierPort":"Hyderabad Air","supplierAddress":"HETERO CORPORATE, NO. 7-2-A2,, HYDERABAD","customerAddress":""},{"dataSource":"API Export","activeIngredients":"","year":"2024","qtr":"Q3","strtotime":1719858600,"product":"BEXAROTENE IH","address":"HETERO CORPORATE, NO. 7-2-A2,","city":"HYDERABAD","supplier":"HETERO DRUGS","supplierCountry":"INDIA","foreign_port":"BUENOS AIRES, BA","customer":"TO THE ORDER OF","customerCountry":"ARGENTINA","quantity":"6.00","actualQuantity":"6","unit":"KGS","unitRateFc":"6695","totalValueFC":"39522.9","currency":"USD","unitRateINR":550626.83333333337,"date":"02-Jul-2024","totalValueINR":"3303761","totalValueInUsd":"39522.9","indian_port":"Hyderabad Air","hs_no":"29163110","bill_no":"2120227","productDescription":"API","marketType":"LESS REGULATED MARKET","country":"ARGENTINA","selfForZScoreResived":"Pharma Grade","supplierPort":"Hyderabad Air","supplierAddress":"HETERO CORPORATE, NO. 7-2-A2,, HYDERABAD","customerAddress":""},{"dataSource":"API Export","activeIngredients":"","year":"2024","qtr":"Q3","strtotime":1720377000,"product":"BEXAROTENE IH","address":"HETERO CORPORATE, NO. 7-2-A2,","city":"HYDERABAD","supplier":"HETERO DRUGS","supplierCountry":"INDIA","foreign_port":"ISTANBUL","customer":"TO THE ORDER OF","customerCountry":"TURKEY","quantity":"2.25","actualQuantity":"2.25","unit":"KGS","unitRateFc":"12000","totalValueFC":"26629","currency":"USD","unitRateINR":989310.40444444446,"date":"08-Jul-2024","totalValueINR":"2225948.41","totalValueInUsd":"26629","indian_port":"Hyderabad Air","hs_no":"29163110","bill_no":"2265256","productDescription":"API","marketType":"LESS REGULATED MARKET","country":"TURKEY","selfForZScoreResived":"Pharma Grade","supplierPort":"Hyderabad Air","supplierAddress":"HETERO CORPORATE, NO. 7-2-A2,, HYDERABAD","customerAddress":""}]
    08-Mar-2021
    08-Jul-2024
    KGS
    overview
    Loading...

    Average Price (USD/KGS)

    Number of Transactions

    Total Quantity (KGS)

    Total Value (USD)

    Quantity (KGS) & Unit rate (USD/KGS) over time

    API Imports and Exports

    Importing Country Total Quantity
    (KGS)    		 Average Price
    (USD/KGS)    		 Number of Transactions

    Upgrade, download data, analyse, strategize, subscribe with us contact

    DRUG PRODUCT COMPOSITIONS

    Do you need Business Intel? Ask us

    DOSAGE - CAPSULE;ORAL - 75MG

    USFDA APPLICATION NUMBER - 21055

    read-more

    DOSAGE - GEL;TOPICAL - 1%

    USFDA APPLICATION NUMBER - 21056

    read-more

    Related Excipient Companies

    Upload your portfolio for free, ask us

    Excipients by Applications

    Click here to find the perfect excipient manufacturers by their capabilities

    Coating Systems & Additives

    read-more
    read-more

    Fillers, Diluents & Binders

    read-more
    read-more

    Controlled & Modified Release

    read-more
    read-more

    Direct Compression

    read-more
    read-more

    Film Formers & Plasticizers

    read-more
    read-more

    Disintegrants & Superdisintegrants

    read-more
    read-more

    Chewable & Orodispersible Aids

    read-more
    read-more

    Parenteral

    read-more
    read-more

    Taste Masking

    read-more
    read-more

    Granulation

    read-more
    read-more

    Solubilizers

    read-more
    read-more

    Thickeners and Stabilizers

    read-more
    read-more

    Empty Capsules

    read-more
    read-more

    Co-Processed Excipients

    read-more
    read-more

    Coloring Agents

    read-more
    read-more

    Topical

    read-more
    read-more

    Vegetarian Capsules

    read-more
    read-more

    API Stability Enhancers

    read-more
    read-more

    Surfactant & Foaming Agents

    read-more
    read-more

    Emulsifying Agents

    read-more
    read-more

    Rheology Modifiers

    read-more
    read-more

    Soft Gelatin

    read-more
    read-more

    Digital Content read-more

    Create Content with PharmaCompass, ask us

    NEWS #PharmaBuzz

    read-more
    read-more

    Global Sales Information

    Do you need Business Intel? Ask us

    Market Place

    Do you need sourcing support? Ask us

    ABOUT THIS PAGE

    Bexarotene Manufacturers

    A Bexarotene manufacturer is defined as any person or entity involved in the manufacture, preparation, processing, compounding or propagation of Bexarotene, including repackagers and relabelers. The FDA regulates Bexarotene manufacturers to ensure that their products comply with relevant laws and regulations and are safe and effective to use. Bexarotene API Manufacturers are required to adhere to Good Manufacturing Practices (GMP) to ensure that their products are consistently manufactured to meet established quality criteria.

    click here to find a list of Bexarotene manufacturers with USDMF, JDMF, KDMF, CEP, GMP, COA and API Price related information on PhamaCompass.

    Bexarotene Suppliers

    A Bexarotene supplier is an individual or a company that provides Bexarotene active pharmaceutical ingredient (API) or Bexarotene finished formulations upon request. The Bexarotene suppliers may include Bexarotene API manufacturers, exporters, distributors and traders.

    click here to find a list of Bexarotene suppliers with USDMF, JDMF, KDMF, CEP, GMP, COA and API Price related information on PharmaCompass.

    Bexarotene USDMF

    A Bexarotene DMF (Drug Master File) is a document detailing the whole manufacturing process of Bexarotene active pharmaceutical ingredient (API) in detail. Different forms of Bexarotene DMFs exist exist since differing nations have different regulations, such as Bexarotene USDMF, ASMF (EDMF), JDMF, CDMF, etc.

    A Bexarotene DMF submitted to regulatory agencies in the US is known as a USDMF. Bexarotene USDMF includes data on Bexarotene's chemical properties, information on the facilities and procedures used, and details about packaging and storage. The Bexarotene USDMF is kept confidential to protect the manufacturer’s intellectual property.

    click here to find a list of Bexarotene suppliers with USDMF on PharmaCompass.

    Bexarotene WC

    A Bexarotene written confirmation (Bexarotene WC) is an official document issued by a regulatory agency to a Bexarotene manufacturer, verifying that the manufacturing facility of a Bexarotene active pharmaceutical ingredient (API) adheres to the Good Manufacturing Practices (GMP) regulations of the importing country. When exporting Bexarotene APIs or Bexarotene finished pharmaceutical products to another nation, regulatory agencies frequently require a Bexarotene WC (written confirmation) as part of the regulatory process.

    click here to find a list of Bexarotene suppliers with Written Confirmation (WC) on PharmaCompass.

    Bexarotene NDC

    National Drug Code is a comprehensive database maintained by the FDA that contains information on all drugs marketed in the US. This directory includes information about finished drug products, unfinished drug products, and compounded drug products, including those containing Bexarotene as an active pharmaceutical ingredient (API).

    Finished drug products

    The FDA updates the NDC directory daily. The NDC numbers for Bexarotene API and other APIs are published in this directory by the FDA.

    Unfinished drugs

    The NDC unfinished drugs database includes product listing information submitted for all unfinished drugs, such as active pharmaceutical ingredients (APIs), drugs intended for further processing and bulk drug substances for compounding.

    Pharmaceutical companies that manufacture Bexarotene as an active pharmaceutical ingredient (API) must furnish the FDA with an updated record of all drugs that they produce, prepare, propagate, compound, or process for commercial distribution in the US at their facilities.

    Compounded drug products

    The NDC directory also contains data on finished compounded human drug products that contain Bexarotene and are produced by outsourcing facilities. While these outsourcing facilities are not mandated to assign a Bexarotene NDC to their finished compounded human drug products, they may choose to do so.

    click here to find a list of Bexarotene suppliers with NDC on PharmaCompass.

    Bexarotene GMP

    Bexarotene Active pharmaceutical ingredient (API) is produced in GMP-certified manufacturing facility.

    GMP stands for Good Manufacturing Practices, which is a system used in the pharmaceutical industry to make sure that goods are regularly produced and monitored in accordance with quality standards. The FDA’s current Good Manufacturing Practices requirements are referred to as cGMP or current GMP which indicates that the company follows the most recent GMP specifications. The World Health Organization (WHO) has its own set of GMP guidelines, called the WHO GMP. Different countries can also set their own guidelines for GMP like China (Chinese GMP) or the EU (EU GMP).

    PharmaCompass offers a list of Bexarotene GMP manufacturers, exporters & distributors, which can be sorted by USDMF, JDMF, KDMF, CEP (COS), WC, API price, and more, enabling you to easily find the right Bexarotene GMP manufacturer or Bexarotene GMP API supplier for your needs.

    Bexarotene CoA

    A Bexarotene CoA (Certificate of Analysis) is a formal document that attests to Bexarotene's compliance with Bexarotene specifications and serves as a tool for batch-level quality control.

    Bexarotene CoA mostly includes findings from lab analyses of a specific batch. For each Bexarotene CoA document that a company creates, the USFDA specifies specific requirements, such as supplier information, material identification, transportation data, evidence of conformity and signature data.

    Bexarotene may be tested according to a variety of international standards, such as European Pharmacopoeia (Bexarotene EP), Bexarotene JP (Japanese Pharmacopeia) and the US Pharmacopoeia (Bexarotene USP).

    Inform the supplier about your product requirements, specifying if you need a product with particular monograph like EP (Ph. Eur.), USP, JP, BP, or any other quality. In addition, clarify whether you need hydrochloride (HCl), anhydricum, base, micronisatum or a specific level of purity. To find reputable suppliers, utilize the filters and select those certified by GMP, FDA, or any other certification as per your requirement.
    For your convenience, we have listed synonyms and CAS numbers to help you find the best supplier. The use of synonyms and CAS numbers can be helpful in identifying potential suppliers, but it is crucial to note that they might not always indicate the exact same product. It is important to confirm the product details with the supplier before making a purchase to ensure that it meets your requirements.
    Ask Us for Pharmaceutical Supplier and Partner
    Ask Us, Find A Supplier / Partner
    No Commissions, No Strings Attached, Get Connected for FREE

    What are you looking for?

    How can we help you?

    The request can't be empty

    Please read our Privacy Policy carefully

    You must agree to the privacy policy

    The name can't be empty
    The company can't be empty.
    The email can't be empty Please enter a valid email.
    The mobile can't be empty

    Market Place

    Market Place

    PharmaCompass

    Home

    Market Place

    Menu

    Post Enquiry

    Post Enquiry

    Market Place

    Market Place

    Search